Novartis gets FDA priority review for malaria drug

15 Sep 2023
Reuters ZURICH, Sept 15 (Reuters) - Swiss drug firm Novartis has won priority review from the U.S. Food and Drug Administration for its Coartem anti-malaria drug.

Novartis said in a statement that Coartem, the leading artemisinin-based combination treatment (ACT) for malaria worldwide that is used widely in Africa, could become the first such treatment approved for use in the United States.

(Reporting by Emma Thomasson)

https://www.reuters.com/article/rbssHealthcareNews/idUSZAT00794120080915